Publications
324 results found
Huus KE, Frankowski M, Pučić-Baković M, et al., 2021, Changes in IgA-targeted microbiota following fecal transplantation for recurrent <i>Clostridioides difficile</i> infection, Gut Microbes, Vol: 13, ISSN: 1949-0976
Mullish BH, Michael DR, McDonald JA, et al., 2021, Identifying the factors influencing outcome in probiotic studies in overweight and obese patients: host or microbiome?, Gut, Vol: 70, Pages: 225-226
Forlano R, Mullish BH, Maurice JB, et al., 2021, NAFLD: Time to apply quantitation in liver biopsies as endpoints in clinical trials, Journal of Hepatology, Vol: 74, Pages: 241-242, ISSN: 0168-8278
Mullish BH, Allegretti JR, 2021, The contribution of bile acid metabolism to the pathogenesis of <i>Clostridioides difficile</i> infection, Therapeutic Advances in Gastroenterology, Vol: 14, Pages: 175628482110177-175628482110177, ISSN: 1756-2848
<jats:p> Clostridioides difficile infection (CDI) remains a major global cause of gastrointestinal infection, with significant associated morbidity, mortality and impact upon healthcare system resources. Recent antibiotic use is a key risk factor for the condition, with the marked antibiotic-mediated perturbations in gut microbiome diversity and composition that underpin the pathogenesis of CDI being well-recognised. However, only relatively recently has further insight been gained into the specific mechanistic links between these gut microbiome changes and CDI, with alteration of gut microbial metabolites – in particular, bile acid metabolism – being a particular area of focus. A variety of in vitro, ex vivo, animal model and human studies have now demonstrated that loss of gut microbiome members with bile-metabolising capacity (including bile salt hydrolases, and 7-α-dehydroxylase) – with a resulting alteration of the gut bile acid milieu – contributes significantly to the disease process in CDI. More specifically, this microbiome disruption results in the enrichment of primary conjugated bile acids (including taurocholic acid, which promotes the germination of C. difficile spores) and loss of secondary bile acids (which inhibit the growth of C. difficile, and may bind to and limit activity of toxins produced by C. difficile). These bile acid changes are also associated with reduced activity of the farnesoid X receptor pathway, which may exacerbate C. difficile colitis throughout its impact upon gut barrier function and host immune/inflammatory response. Furthermore, a key mechanism of efficacy of faecal microbiota transplant (FMT) in treating recurrent CDI has been shown to be restoration of gut microbiome bile metabolising functionality; ensuring the presence of this functionality among defined microbial communities (and other ‘next generation’ FMT products) designed to treat CDI may be critical to their success. &
Forlano R, Mullish BH, Nathwani R, et al., 2020, Non-Alcoholic Fatty Liver Disease and Vascular Disease, Current Vascular Pharmacology, Vol: 19, Pages: 269-279, ISSN: 1570-1611
<jats:sec><jats:title /><jats:p>Non-Alcoholic Fatty Liver Disease (NAFLD) represents an increasing cause of liver diseaseworldwide. However, notably, the primary cause of morbidity and mortality in patients with NAFLD iscardiovascular disease (CVD), with fibrosis stage being the strongest disease-specific predictor. It isglobally projected that NAFLD will become increasingly prevalent, especially among children andyounger adults. As such, even within the next few years, NAFLD will contribute considerably to theoverall CVD burden.In this review, we discuss the role of NAFLD as an emerging risk factor for CVD. In particular, thisarticle aims to provide an overview of pathological drivers of vascular damage in patients with NAFLD.Moreover, the impact of NAFLD on the development, severity and the progression of subclinical andclinical CVD will be discussed. Finally, the review illustrates current and potential future perspectivesto screen for CVD in this high-risk population.</jats:p></jats:sec>
Innes AJ, Ghani R, Mullish BH, et al., 2020, O105. Faecal microbiota transplant (FMT) can reduce the high NRM associated with multi-drug resistant organism (MDRO) colonisation prior to allogeneic HCT., The 46th Annual Meeting of the European Society for Blood and Marrow Transplantation, Publisher: Springer Nature [academic journals on nature.com], Pages: 122-122, ISSN: 0268-3369
Smith PJ, 2020, GI highlights from the literature, Gut, Vol: 69, Pages: 2256-2257, ISSN: 0017-5749
Baunwall SMD, Lee MM, Eriksen MK, et al., 2020, Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis, EClinicalMedicine, Vol: 29-30, Pages: 100642-100642, ISSN: 2589-5370
Martinez-Gili L, McDonald JAK, Liu Z, et al., 2020, Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent <i>Clostridioides difficile</i> infection and beyond: the contribution of gut microbial-derived metabolites, Gut Microbes, Vol: 12, Pages: 1810531-1810531, ISSN: 1949-0976
Miguens Blanco J, Selvarajah U, Liu Z, et al., 2020, Identification of New Associations Between Psoriatic Arthritis and the Gut Microbiota. the Mi-PART, a Phenomic Study, ACR Convergence 2020, Publisher: Wiley, ISSN: 2326-5205
Allegretti JR, Kelly CR, Grinspan A, et al., 2020, Outcomes of Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Diseases and Recurrent Clostridioides difficile Infection, Gastroenterology, Vol: 159, Pages: 1982-1984, ISSN: 0016-5085
Craven LJ, McIlroy JR, Mullish BH, et al., 2020, Letter: Intestinal microbiota transfer – Updating the nomenclature to increase acceptability, Alimentary Pharmacology and Therapeutics, Vol: 52, Pages: 1622-1623, ISSN: 0269-2813
This article is linked to Lai et al paper. To view this article, visit https://doi.org/10.1111/apt.15116
Ghani R, Mullish BH, 2020, Decision: Considerations for Use of Fecal Microbiota Transplantation in Special Patient Populations, The 6 Ds of Fecal Microbiota Transplantation: A Primer from Decision to Discharge and Beyond, Editors: Allegretti, Kassam, Publisher: Slack Incorporated, ISBN: 9781630917500
Mullish BH, 2020, The Role of Fecal Microbiota Transplantation in the Treatment of Obesity, Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease, The 6 Ds of Fecal Microbiota Transplantation: A Primer from Decision to Discharge and Beyond, Editors: Allegretti, Kassam, Publisher: Slack Incorporated, ISBN: 9781630917500
Alexander JL, Mullish BH, 2020, A Guide to the Gut Microbiome and its Relevance to Critical Care, British Journal of Nursing, Vol: 29, Pages: 1106-1112, ISSN: 0966-0461
<jats:p> Although it is well-established that particular bacteria may cause gastroenteritis and other infections when present in the gut, it is only recently that scientists have made significant inroads into understanding the huge number of other bacteria and additional microbes that live within the gastrointestinal tract, referred to as the gut microbiome. In particular, it is now recognised that bacteria within the gut microbiome have a wide variety of roles in maintaining different aspects of human health, and that disturbances of these bacteria may potentially cause or contribute to a number of different medical conditions, including particular infections, certain cancers, and chronic conditions, including inflammatory bowel disease. Moreover, there is increasing awareness that these bacteria help determine how the body responds to medication, including antibiotics and chemotherapy. There has been growing interest in different approaches to alter the gut microbiome as a novel approach to medical therapy. This article provides an overview of the importance of the gut microbiome, with a particular focus on critical care. </jats:p>
Forlano R, Mullish BH, Mukherjee SK, et al., 2020, In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19, PLOS ONE, Vol: 15, Pages: e0240400-e0240400
Forlano R, Mullish B, Mukherjee S, et al., 2020, 450 - In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19, Hepatology, Vol: 72, Pages: 282A-283A, ISSN: 0270-9139
Allegretti JR, Kelly C, Grinspan AM, et al., 2020, S0650 Fecal Microbiota Transplantation Decolonizes C. difficile in Patients With Inflammatory Bowel Disease and Concomitant C. difficile Infection, Publisher: Ovid Technologies (Wolters Kluwer Health), Pages: S326-S326, ISSN: 0002-9270
Ianiro G, Mullish BH, Kelly CR, et al., 2020, Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic, Gut, Vol: 69, Pages: 1555-1563, ISSN: 0017-5749
<jats:p>The COVID-19 pandemic has led to an exponential increase in SARS-CoV-2 infections and associated deaths, and represents a significant challenge to healthcare professionals and facilities. Individual countries have taken several prevention and containment actions to control the spread of infection, including measures to guarantee safety of both healthcare professionals and patients who are at increased risk of infection from COVID-19. Faecal microbiota transplantation (FMT) has a well-established role in the treatment of<jats:italic>Clostridioides difficile</jats:italic>infection. In the time of the pandemic, FMT centres and stool banks are required to adopt a workflow that continues to ensure reliable patient access to FMT while maintaining safety and quality of procedures. In this position paper, based on the best available evidence, worldwide FMT experts provide guidance on issues relating to the impact of COVID-19 on FMT, including patient selection, donor recruitment and selection, stool manufacturing, FMT procedures, patient follow-up and research activities.</jats:p>
McIlroy JR, Mullish BH, Goldenberg SD, et al., 2020, Intestinal microbiome transfer, a novel therapeutic strategy for COVID-19 induced hyperinflammation?, Clinical Immunology, Vol: 218, Pages: 108542-108542, ISSN: 1521-6616
Smith PJ, 2020, GI highlights from the literature, Gut, Vol: 69, Pages: 1533-1534, ISSN: 0017-5749
Nathwani R, Mukherjee S, Forlano R, et al., 2020, Letter: liver disease and COVID‐19—not the perfect storm, Alimentary Pharmacology & Therapeutics, Vol: 52, Pages: 572-574, ISSN: 0269-2813
<jats:p><jats:bold>LINKED CONTENT</jats:bold></jats:p><jats:p>This article is linked to Garrido et al papers. To view these articles, visit <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1111/apt.15813">https://doi.org/10.1111/apt.15813</jats:ext-link> and <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1111/apt.15886">https://doi.org/10.1111/apt.15886</jats:ext-link>.</jats:p>
Forlano R, Mullish BH, Giannakeas N, et al., 2020, High-Throughput, Machine Learning–Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease, Clinical Gastroenterology and Hepatology, Vol: 18, Pages: 2081-2090.e9, ISSN: 1542-3565
Woodhouse C, Edwards L, Mullish BH, et al., 2020, Results of the PROFIT trial, a PROspective randomised placebo-controlled feasibility trial of Faecal mIcrobiota Transplantation in advanced cirrhosis, Publisher: Elsevier BV, Pages: S77-S78, ISSN: 0168-8278
Segal JP, Mullish BH, Quraishi MN, et al., 2020, Letter: faecal microbiota transplantation for IBS, Alimentary Pharmacology & Therapeutics, Vol: 52, Pages: 556-557, ISSN: 0269-2813
<jats:p><jats:bold>LINKED CONTENT</jats:bold></jats:p><jats:p>This article is linked to Lahtinen et al papers. To view these articles, visit<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1111/apt.15810">https://doi.org/10.1111/apt.15810</jats:ext-link> and <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1111/apt.15875">https://doi.org/10.1111/apt.15875</jats:ext-link>.</jats:p>
Ianiro G, Segal JP, Mullish BH, et al., 2020, Fecal microbiota transplantation in gastrointestinal and extraintestinal disorders, Future Microbiology, ISSN: 1746-0913
Ianiro G, Mullish BH, Kelley CR, 2020, Correction to <i>Lancet Gastroenterol Hepatol</i> 2020; 5: 430-31, LANCET GASTROENTEROLOGY & HEPATOLOGY, Vol: 5, Pages: E5-E5
Allegretti JR, Hurtado J, Carrellas M, et al., 2020, 121 ULCERATIVE COLITIS PATIENTS ACHEIVE MORE ROBUST ENGRAFTMENT COMPARED TO PATIENTS WITH CROHN'S DISEASE AFTER FECAL MICROBIOTA TRANSPLANTATION FOR THE TREATMENT OF RECURRENT C. DIFFICLE INFECTION, Gastroenterology, Vol: 158, Pages: S-22, ISSN: 0016-5085
Martinez-Gili L, McDonald JA, Liu Z, et al., 2020, 644 IDENTIFICATION OF NOVEL CHANGES IN MICROBIALLY-DERIVED METABOLITES AFTER FECAL MICROBIOTA TRANSPLANT FOR RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION, Publisher: Elsevier BV, ISSN: 0016-5085
Ghani R, Mullish BH, McDonald JA, et al., 2020, 1144 FECAL MICROBIOTA TRANSPLANT FOR MULTI-DRUG RESISTANT ORGANISMS: IMPROVED CLINICAL OUTCOMES BEYOND INTESTINAL DECOLONISATION, Publisher: Elsevier BV, ISSN: 0016-5085
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.